Evaluating the Impact of Semaglutide on Stroke Risk Reduction in Cardiovascular High-Risk Populations: A Systematic Review and Meta-analysis
DOI:
https://doi.org/10.58600/eurjther2817Keywords:
anti-diabetic drugs, cardiovascular diseases, drug, meta-analysisAbstract
Objective: While several meta-analyses have evaluated the cardiovascular (CV) and renal benefits of GLP-1 receptor agonists, including semaglutide, none have specifically investigated its impact on stroke risk reduction. This meta-analysis aims to evaluate the overall effect of semaglutide on reducing stroke risk among populations at high CV-risk.
Methods: A comprehensive search was undertaken across PubMed, Scopus, and Cochrane databases up to May 2024. Four eligible studies included randomized controlled trials (RCTs) that compared semaglutide with placebo for cardiovascular outcomes in both diabetic and non-diabetic populations. Primary cerebrovascular endpoints included stroke and its subtypes. Secondary cardiovascular endpoints were all-cause mortality, major adverse cardiovascular events (MACE), and CV-mortality. Statistical analysis was conducted using Review Manager 5.4 and the risk ratios (RR) with 95% confidence interval (CI) were computed employing a random-effects model.
Results: Semaglutide demonstrated a modest reduction in stroke risk (RR 0.84, 95% CI 0.70–1.00, P=0.050, I²=21%), approaching statistical significance. It also demonstrated significant benefits in reducing all-cause mortality (RR 0.81, 95% CI 0.70-0.94, P=0.006, I2=42%), MACE (RR 0.81, 95% CI 0.74-0.88, P<0.001, I2=0%), and cardiovascular mortality (RR 0.79, 95% CI 0.67-0.93, P=0.006, I2=28%).
Conclusion: The secondary outcomes were significantly reduced, stroke risk reduction was marginal, highlighting semaglutide’s promising vascular benefits. The inclusion of only four RCTs and moderate heterogeneity among the trials may limit the generalizability of these findings.
References
World Health Organization. Stroke, Cerebrovascular Accident. World Health Organization – Regional Office for the Eastern Mediterranean. 2022. Available from: https://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/
Stroke Awareness Foundation. Stroke Facts & Statistics. Stroke Awareness Foundation. 2019. Available from: https://www.strokeinfo.org/stroke-facts-statistics/
National Institutes of Health. How many people are affected by/at risk for stroke? NIH. 2016. Available from: https://www.nichd.nih.gov/health/topics/stroke/conditioninfo/risk
Potter TBH, Tannous J, Vahidy FS (2022) A contemporary review of epidemiology, risk factors, etiology, and outcomes of premature stroke. Curr Atheroscler Rep. 24(12):939–948. https://doi.org/10.1007/s11883-022-01067-x
Saini V, Guada L, Yavagal DR (2021) Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology. 97(20 Suppl 2):S6–S16. https://doi.org/10.1212/WNL.0000000000012781
Esenwa C, Gutierrez J (2015) Secondary stroke prevention: challenges and solutions. Vasc Health Risk Manag. 11:437–450. https://doi.org/10.2147/VHRM.S63791
Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI (2019) Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. J Diabetes Investig. 10(3):780–792. https://doi.org/10.1111/jdi.12932
Tan HC, Dampil OA, Marquez MM (2022) Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 37(2):65–72. https://doi.org/10.15605/jafes.037.02.14
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 389(24):2221–2232. https://doi.org/10.1056/NEJMoa2307563
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, et al. (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141
Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, et al. (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 391(17):1573–1583. https://doi.org/10.1056/NEJMoa2403664
Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, et al. (2023) Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 402(10403):705–719. https://doi.org/10.1016/S0140-6736(23)01185-6
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, et al. (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 389(12):1069–1084. https://doi.org/10.1056/NEJMoa2306963
Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ (2025) Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. Published online Jan 31. https://doi.org/10.1016/j.amjmed.2025.01.021
Temporelli PL (2025) Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with type 2 diabetes. Eur Heart J Suppl. 27(Suppl 1):i1–i5. https://doi.org/10.1093/eurheartjsupp/suae086
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, et al. (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 381(9):841–851. https://doi.org/10.1056/NEJMoa1901118
Evans M, Husain M, Srivastava A, Mangla KK, Kuhlman AB, Lingvay I (2024) Risk of stroke in real-world US individuals with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase 4 inhibitor. Adv Ther. 41(5):1843–1859. https://doi.org/10.1007/s12325-023-02750-4
Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, et al. (2022) Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6 trials. Stroke. 53(9):2749–2757. https://doi.org/10.1161/STROKEAHA.121.037775
American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 46(Suppl 1):S1–S290. https://doi.org/10.2337/dc23-Sint
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, et al. (2023) ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 45(7):518. https://doi.org/10.1093/eurheartj/ehad192
Duan CM, Wan TF, Wang Y, Yang QW (2019) Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: a systematic review and meta-analysis. Med (Baltim). 98(46):e17860. https:/doi.org/10.1097/MD.0000000000017860
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, et al. (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 391(2):109-121. https://doi.org/10.1056/NEJMoa2403347
Downloads
Published
How to Cite
License
Copyright (c) 2025 Laiba Nasir, Laiba Jalal, Ayesha Siddiqa, Aiman Nasir, Maryam Farooqui, Abdul Hannan Siddiqui
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
